International Journal of Surgical Oncology / 2014 / Article / Tab 1

Review Article

The Treatment of Peritoneal Carcinomatosis in Advanced Gastric Cancer: State of the Art

Table 1

Comparing main studies in terms of median survival, 5-year survival rates, and morbidity.

Authors Year publishedType of studyStage of GCNumber of patientsType of protocolMedian survival (months)5-year survival ratesMorbidity

Fujimoto et al. [21]1999RCTStage II-III 141HIPEC + surgery versus surgery aloneN/A76% versus 57%N/A
Kim and Bae [7]2001PCSStage III-IV103HIPEC + CRS versus surgery alone36 versus 22.932.7% versus 27.1%33.2% versus 36.5%
Yonemura et al. [8]2001RCTStage II-III 139HIPEC + surgery versus NIC + surgery versus surgery aloneN/A61% versus 43% versus 42%4% versus 0% versus 4%
Yonemura et al. [9]2009PCSStage III-IV79NIPS versus NIPS + surgeryN/A20.4% versus 40%*11.4%
Glehen et al. [10]2010 RCSStage III-IV159HIPEC + EPIC versus EPIC
HIPEC
9.2 (overall)13% (overall)27.8% (overall)

HIPEC: hyperthermic intraperitoneal chemotherapy; EPIC: early postoperative intraperitoneal chemotherapy; PIC: perioperative intraperitoneal chemotherapy; NIC: normothermic intraperitoneal chemotherapy; NIPS: neoadjuvant intraperitoneal and systemic chemotherapy; NIIC: normothermic Intraoperative Intraperitoneal Chemotherapy; DPIC: Delayed Postoperative Intraperitoneal Chemotherapy; RCS: Retrospective Case Series; PCS: Prospective cohort study; PCS: prospective case series; N/A: not available. 
*2-year survival rates.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.